BDRX: Initiating Coverage of Biodexa Pharmaceuticals; A Deep Value Oncology Platform Built Around Two High-Conviction Areas [Yahoo! Finance]
Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
Company Research
Source: Yahoo! Finance
We are initiating coverage of Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) with a valuation of $7.00. Biodexa is a clinical-stage GI oncology company focused on developing differentiated therapies for rare and difficult-to-treat cancers. The company's strategy centers on advancing scientifically validated mechanisms with the potential to address clear unmet medical needs, particularly in settings where existing therapies provide only transient benefit or have permanent life-altering impact on quality of life. Biodexa's pipeline is anchored by two core assets: MTX240, a novel molecular glue therapy targeting the PDE3A–SLFN12 axis with potential applications in gastrointestinal stromal tumors (GIST) and other malignancies, and MTX230 (eRAPA), a reformulated version of the mTOR inhibitor rapamycin that is currently in a registrational Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP). We believe Biodexa represents a compelling deep value opportunity, with
Show less
Read more
Impact Snapshot
Event Time:
BDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDRX alerts
High impacting Biodexa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BDRX
News
- Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial SuppliesGlobeNewswire
- Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP PatientsBusiness Wire
- Biodexa Pharmaceuticals (BDRX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BDRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Preliminary Results for the Year Ended 31 December 2025 [Yahoo! Finance]Yahoo! Finance
- Preliminary Results for the Year Ended 31 December 2025GlobeNewswire
BDRX
Sec Filings
- 3/31/26 - Form EFFECT
- 3/31/26 - Form EFFECT
- 3/31/26 - Form EFFECT
- BDRX's page on the SEC website